BIOVERSYS N overview

BioVersys AG / Key word(s): Conference BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025 08.04.2025 / 07:00 CET/CEST Basel, Switzerland. April 08, 2025, 7am CEST . Oral presentation on April 13, 2025, highlighting positive BV100 Phase 2 VABP trial read-out with excellent efficacy and safety data Complementary poster presentations featuring clinical & preclinical data from BV100 on Acinetobacter baumannii and preclinical BV500 on non-tuberculosis mycobacterium (NTM) BioVersys...

BioVersys AG / Key word(s): Patent BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE 31-March-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 31, 2025, 7am CET Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV formulation technology in...

BioVersys AG / Key word(s): Annual Results BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024 26-March-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 26, 2025, 7am CET BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy data Alpibectir: Phase 2a EBA trial delivered very...

BioVersys AG / Key word(s): Miscellaneous FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL 19-March-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 19, 2025, 7am CET. Ad hoc announcement pursuant to Art. 53 LR Under the BioVersys and GSK...

BioVersys AG / Key word(s): Annual Results BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS 14.03.2025 / 07:00 CET/CEST Basel, Switzerland. March 14, 2025, 7am CET BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today the reporting date for its Full-Year 2024...

BioVersys AG / Key word(s): IPO Bioversys announces partial exercise of over-allotment option 10-March-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 10, 2025, 7am CET. Ad hoc announcement pursuant to Art. 53 LR Partial exercise of over-allotment option following end of stablization period in context of the company’s initial...

BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead candidates with demonstrated broad-spectrum in vitro and in vivo efficacy against non-tuberculous mycobacteria (NTM). Continued strategic support from LifeArc through the CF AMR Syndicate Collaborative Discovery Programme (CDP), accelerating the development of novel therapies for difficult-to-treat NTM lung disease in cystic fibrosis (CF) patients. Leveraging its proprietary Ansamycin...

BioVersys AG / Key word(s): Miscellaneous BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE 11.02.2025 / 07:00 CET/CEST Basel, Switzerland. February 11, 2025, 7am CET BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead candidates with demonstrated broad-spectrum in vitro and in vivo efficacy against non-tuberculous mycobacteria (NTM). Continued strategic support from LifeArc through the CF AMR...